Effect and Mechanism of Dopamine on Ulcerative Colitis

Overview

Increased evidence suggests that dopamine acts as an important regulator of immune function. A substantial amount of dopamine exists in the gastrointestinal tract, especially in colonic lumen. Decreased dopamine level has been reported in the colonic mucosa of ulcerative colitis patients. Therefore, the investigators suppose that colonic dopamine could involve in the ulcerative colitis and play an important role. This study aims to explore the role of dopamine in ulcerative colitis and underlying mechanism, which will provide a rationale for diagnosis and treatment of the ulcerative colitis.

Study Type

• Study Type: Observational
• Study Design
  • Time Perspective: Prospective
• Study Primary Completion Date: August 30, 2022

Detailed Description

This study is a case-control clinical study. 30 patients with non-ulcerative colitis examined by endoscopy were selected as the control group. According to the inclusion and exclusion criteria, 30 patients with ulcerative colitis were determined. The baseline data of patients were recorded objectively: name, sex, age, vital signs, body weight and stool condition (frequency, character, etc.). Some laboratory examination results (blood routine, fecal routine and fecal culture, liver function, blood coagulation function, electrolyte, etc.), ulcerative colitis lesion range, ulcerative colitis classification and related history (common disease, treatment history and life history). Colonic mucosal tissue samples of patients with ulcerative colitis and control group were obtained by colonoscopic biopsy. The degree of inflammation was evaluated by related inflammatory factors via ELISA. The changes of dopamine system was detected by HPLC-ECD, Western Blot and immunohistochemistry. This study aims to provide new diagnostic and therapeutic basis, select appropriate drug delivery through clarify the effect and mechanism of local dopamine on colitis.

Interventions

• Other: Patients diagnosed with ulcerative colitis
  • Patients with ulcerative colitis diagnosed by endoscopy and histopathology

Arms, Groups and Cohorts

• Ulcerative colitis group
  • Patients with ulcerative colitis as observation group
• Non-ulcerative colitis group
  • Non-ulcerative colitis as control group

Clinical Trial Outcome Measures

Primary Measures

• Comparison of the levels of inflammatory factors in colonic mucosa
  • Time Frame: 1 day
  • The levels of inflammatory factors in colonic mucosa of ulcerative colitis group and non-ulcerative colitis control group were detected by Elisa to evaluate the degree of inflammation.
• Comparison of dopamine content in colonic mucosa
  • Time Frame: 1 day
  • HPLC-ECD was used to detect and compare the content of dopamine in colonic mucosa between ulcerative colitis group and non-ulcerative colitis group.

Participating in This Clinical Trial

Inclusion Criteria

1. Patients with or without ulcerative colitis diagnosed by endoscopy and histopathology 2. Negative bacterial culture in stool 3. Written informed consent Exclusion Criteria:

1. Patients with cardiovascular and cerebrovascular diseases, or patients with severe impairment of liver, kidney and hematopoietic system 2. Mental patients 3. Hemorrhagic diseases 4. Platelet count < 50 × 10 ^ 9 / L 5. Allergic constitution 6. unable to tolerate or cooperate with endoscopy 7. Patients with serious complications, such as intestinal obstruction, intestinal perforation, toxic colonic dilatation, colorectal cancer, etc. 8. Pregnant or lactating women

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

• Lead Sponsor
  • Affiliated Hospital to Academy of Military Medical Sciences
• Provider of Information About this Clinical Study
  • Sponsor
• Overall Official(s)
  • Yan Liu, MD, Principal Investigator, Beijing 302 Hospital